AUTHOR=van den Broek Daan , Hiltermann T. Jeroen N. , Biesma Bonne , Dinjens Winand N. M. , 't Hart Nils A. , Hinrichs John W. J. , Leers Mathie P. G. , Monkhorst Kim , van Oosterhout Matthijs , Scharnhorst Volkher , Schuuring Ed , Speel Ernst-Jan M. , van den Heuvel Michel M. , van Schaik Ron H. N. , von der Thüsen Jan , Willems Stefan M. , de Visser Leonie , Ligtenberg Marjolijn J. L. TITLE=Implementation of Novel Molecular Biomarkers for Non-small Cell Lung Cancer in the Netherlands: How to Deal With Increasing Complexity JOURNAL=Frontiers in Oncology VOLUME=9 YEAR=2020 URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2019.01521 DOI=10.3389/fonc.2019.01521 ISSN=2234-943X ABSTRACT=

The diagnostic landscape of non-small cell lung cancer (NSCLC) is changing rapidly with the availability of novel treatments. Despite high-level healthcare in the Netherlands, not all patients with NSCLC are tested with the currently relevant predictive tumor markers that are necessary for optimal decision-making for today's available targeted or immunotherapy. An expert workshop on the molecular diagnosis of NSCLC involving pulmonary oncologists, clinical chemists, pathologists, and clinical scientists in molecular pathology was held in the Netherlands on December 10, 2018. The aims of the workshop were to facilitate cross-disciplinary discussions regarding standards of practice, and address recent developments and associated challenges that impact future practice. This paper presents a summary of the discussions and consensus opinions of the workshop participants on the initial challenges of harmonization of the detection and clinical use of predictive markers of NSCLC. A key theme identified was the need for broader and active participation of all stakeholders involved in molecular diagnostic services for NSCLC, including healthcare professionals across all disciplines, the hospitals and clinics involved in service delivery, healthcare insurers, and industry groups involved in diagnostic and treatment innovations. Such collaboration is essential to integrate different technologies into molecular diagnostics practice, to increase nationwide patient access to novel technologies, and to ensure consensus-preferred biomarkers are tested.